Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.52 USD | +1.33% | +7.04% | -86.02% |
Financials (USD)
Sales 2024 * | 39.35M | Sales 2025 * | 58.17M | Capitalization | 83.5M |
---|---|---|---|---|---|
Net income 2024 * | -119M | Net income 2025 * | -78M | EV / Sales 2024 * | -1.12 x |
Net cash position 2024 * | 127M | Net cash position 2025 * | 54.53M | EV / Sales 2025 * | 0.5 x |
P/E ratio 2024 * |
-0.77
x | P/E ratio 2025 * |
-1.47
x | Employees | 166 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.02% |
Latest transcript on Marinus Pharmaceuticals, Inc.
1 day | +1.33% | ||
1 week | +7.04% | ||
Current month | +7.04% | ||
1 month | +6.29% | ||
3 months | -82.82% | ||
6 months | -82.12% | ||
Current year | -86.02% |
Managers | Title | Age | Since |
---|---|---|---|
Scott Braunstein
CEO | Chief Executive Officer | 60 | 18-09-04 |
Steven Pfanstiel
DFI | Director of Finance/CFO | 51 | 21-04-11 |
Joseph Hulihan
CTO | Chief Tech/Sci/R&D Officer | 68 | 19-11-05 |
Members of the board | Title | Age | Since |
---|---|---|---|
Tim Mayleben
BRD | Director/Board Member | 63 | 08-11-30 |
Scott Braunstein
CEO | Chief Executive Officer | 60 | 18-09-04 |
Elan Ezickson
BRD | Director/Board Member | 60 | 19-12-11 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.96% | 11 M€ | -6.03% | - | |
0.02% | 0 M€ | 0.00% | - | |
0.02% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 1.52 | +1.33% | 522,876 |
24-06-06 | 1.5 | -2.60% | 384,898 |
24-06-05 | 1.54 | +6.94% | 738,867 |
24-06-04 | 1.44 | -2.70% | 693,863 |
24-06-03 | 1.48 | +4.23% | 1,117,657 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-86.02% | 83.5M | |
+45.82% | 765B | |
-6.16% | 354B | |
+19.86% | 331B | |
+9.32% | 299B | |
+18.45% | 248B | |
-0.78% | 219B | |
+11.88% | 216B | |
+5.90% | 164B | |
-0.73% | 162B |
- Stock Market
- Equities
- MRNS Stock